← Leaderboards
Dean G Tang
University Of Texas Md Anderson Can Ctr
$12,952,203
Attributed
$12,952,203
Total exposure
13
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,952,203 · 13
By mechanism
R01$10,387,644 · 6
R21$1,644,213 · 4
P30$920,346 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Peter F Thall$4,683,294
- Felipe Samaniego$2,780,803
- Sara S. Strom$4,426,461
- Patricia Ann Thompson-Carino$8,608,763
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResistanceMolecularCancer CellCellsMalignant NeoplasmsMalignant Neoplasm Of ProstateStem CellsBiologicalCancer Stem CellHeterogeneityProstate Cancer CellProstateMediatingProteinsReportingTumorigenicResponseCancer PatientBaseAndrogen AntagonistsCastrationNeoplastic CellProperty
Grant awards (48)
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells$473,358
R01 · FY2025 · CA · contact PI
Developmental Therapeutics$372,411
P30 · FY2025 · CA · contact PI
Developmental Therapeutics$44,983
P30 · FY2024 · CA · contact PI
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPC$424,811
R01 · FY2023 · CA · contact PI
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells$423,501
R01 · FY2023 · CA · contact PI
Bioanalytics, Metabolomics and Pharmacokinetics Shared Resource$135,568
P30 · FY2023 · CA · contact PI
Developmental Therapeutics$42,341
P30 · FY2023 · CA · contact PI
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPC$424,811
R01 · FY2022 · CA · contact PI
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells$423,743
R01 · FY2022 · CA · contact PI
Bioanalytics, Metabolomics and Pharmacokinetics Shared Resource$142,608
P30 · FY2022 · CA · contact PI
Developmental Therapeutics$44,540
P30 · FY2022 · CA · contact PI
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPC$433,481
R01 · FY2021 · CA · contact PI
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells$432,651
R01 · FY2021 · CA · contact PI
Correlative efficacy, biomarker, and mechanistic studies associated with a phase Ib/II clinical trial of treating mCRPC patients with enzalutamide and Venetoclax$245,017
R21 · FY2021 · CA · contact PI
Developmental Therapeutics$45,965
P30 · FY2021 · CA · contact PI
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells$440,230
R01 · FY2020 · CA · contact PI
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPC$433,481
R01 · FY2020 · CA · contact PI
Correlative efficacy, biomarker, and mechanistic studies associated with a phase Ib/II clinical trial of treating mCRPC patients with enzalutamide and Venetoclax$204,181
R21 · FY2020 · CA · contact PI
Developmental Therapeutics$45,965
P30 · FY2020 · CA · contact PI
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells$444,510
R01 · FY2019 · CA · contact PI
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPC$433,481
R01 · FY2019 · CA · contact PI
Slow-cycling cells, therapy resistance and clinical implications in prostate cancer$217,473
R21 · FY2019 · CA · contact PI
Developmental Therapeutics$45,965
P30 · FY2019 · CA · contact PI
Slow-cycling cells, therapy resistance and clinical implications in prostate cancer$186,833
R21 · FY2018 · CA · contact PI
Decoding NanogP8 in Tumorigenesis$253,216
R01 · FY2016 · CA · contact PI
Decoding NanogP8 in Tumorigenesis$99,292
R01 · FY2016 · CA · contact PI
Decoding NanogP8 in Tumorigenesis$327,850
R01 · FY2015 · CA · contact PI
Decoding NanogP8 in Tumorigenesis$318,015
R01 · FY2014 · CA · contact PI
Decoding NanogP8 in Tumorigenesis$308,179
R01 · FY2013 · CA · contact PI
Decoding NanogP8 in Tumorigenesis$327,850
R01 · FY2012 · CA · contact PI
Regulation of PCa Stem/Progenitor Cells and Tumor Development by miR-34a$200,004
R21 · FY2011 · CA · contact PI
Nucleotide Regulation of Apaf-1 Apoptosome and Apoptosis$326,744
R01 · FY2010 · ES · contact PI
Regulation of PCa Stem/Progenitor Cells and Tumor Development by miR-34a$171,825
R21 · FY2010 · CA · contact PI
Nucleotide Regulation of Apaf-1 Apoptosome and Apoptosis$330,044
R01 · FY2009 · ES · contact PI
Nucleotide Regulation of Apaf-1 Apoptosome and Apoptosis$330,044
R01 · FY2008 · ES · contact PI
15-Lipoxygenase 2 is a Prostate Senescence Gene$274,534
R01 · FY2008 · AG · contact PI
A Novel Mechanism to Regulate Caspase-8 Activation on the Mitochondrial Membrane$226,380
R21 · FY2008 · ES · contact PI
Nucleotide Regulation of Apaf-1 Apoptosome and Apoptosis$336,780
R01 · FY2007 · ES · contact PI
15-Lipoxygenase 2 is a Prostate Senescence Gene$280,138
R01 · FY2007 · AG · contact PI
A Novel Mechanism to Regulate Caspase-8 Activation on the Mitochondrial Membrane$192,500
R21 · FY2007 · ES · contact PI
15-Lipoxygenase 2 is a Prostate Senescence Gene$288,504
R01 · FY2006 · AG · contact PI
15-Lipoxygenase 2 is a Prostate Senescence Gene$295,448
R01 · FY2005 · AG
15-Lipoxygenase 2 is a Prostate Senescence Gene$295,448
R01 · FY2004 · AG
MITOCHONDRIA SIGNALED APOPTOSIS IN PROSTATE CANCER CELLS$241,500
R01 · FY2004 · CA
MITOCHONDRIA SIGNALED APOPTOSIS IN PROSTATE CANCER CELLS$241,500
R01 · FY2003 · CA
MITOCHONDRIA SIGNALED APOPTOSIS IN PROSTATE CANCER CELLS$241,500
R01 · FY2002 · CA
MITOCHONDRIA SIGNALED APOPTOSIS IN PROSTATE CANCER CELLS$241,500
R01 · FY2001 · CA
MITOCHONDRIA SIGNALED APOPTOSIS IN PROSTATE CANCER CELLS$241,500
R01 · FY2000 · CA